Floatz logo

Sargramostim

Chronic Phase Chronic Myelogenous Leukemia

Virginia Commonwealth Universityprotein_peptidePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

86 Active assets in the Chronic Phase Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →